Reference
- van Liessum P A, de Mulder P HM, de Haan LD. Nausea and vomting induced by cytostatic agents. Scand J Gastroenterol 1989; 24: 106–111, Suppl 171
- Lip H. Ondansetron, a new antiemetic therapy for oncology. Scand J Gastroenterol 1990; 25: 55–61, Suppl 178
- Farthing M JG. 5-Hydroxytryptamine (5-HT) and 5-HT3 receptor antagonists. Scand J Gastroenterol 1991; 26: 92–100, Suppl 188
- Kilpatrick G J, Jones B J, Tyers MB. The distribution of specific GR 65630 binding to the brains of several species. Characterisation of binding to rat area postrema and vagus nerve. Eur J Pharmacol 1989; 169: 157–164
- Cubeddu L X, Hoffman I S, Fuenmayor N T, Finn Al. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 1990; 322: 810–816
- Feldberg W, Ton CC. Distribution of 5-hydroxy-tryptamine (serotonin, enteramine) in the wall of the digestive tract. J Physiol (Lond) 1953; 119: 352–362
- Resnick R H, Gray SJ. Distribution of serotonin (5-hydroxytryptamine) in the human gastrointestinal tract. Gastroenterology 1961; 41: 119–121
- Marty M. Ondansetron in the prophylaxis of acute cisplatin-induced nausea and vomiting. Eur J Cancer Clin Oncol 1989; 25: S41–S45, Suppl 1
- Marty M, Pouillart P, Scholl S, et al. Comparison of the 5-hydroxytryptamine-3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclo-pramide in the control of cisplatin-induced emesis. N Engl J Med 1990; 322: 816–821
- Schmoll HJ. The role of ondansetron in the treatment of emesis induced by non-cisplatin-containing chemotherapy regimes. Eur J Cancer Clin Oncol 1989; 25: S35–S39, Suppl 1
- Kaasa S, Kvaloy S, Dicato M A, et al. A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. Eur J Cancer 1990; 26: 311–314
- Priestman TJ. Clinical studies with ondansetron in the control of radiation-induced emesis. Eur J Cancer Clin Oncol 1989; 25: S29–S33, Suppl 1
- Larijani G E, Gratz I, Jacobi A G, et al. Randomized, double-blind comparison of ondansetron and placebo in the treatment of post-operative nausea and vomiting. Anesthesiology 1990; 73: A33
- McKenzie R, Odell S, Rudy S NA, Joslyn AF. Ondansetron, a selective serotonin type 3 (5-HT3) antagonist reduces nausea and vomiting in females following major gynecologic surgery. Anesthesiology 1990; 73: A739
- Talley N J, Phillips SF, Haddad A, et al. Effect of selective 5HT3 antagonist (GR 38032F) on small intestinal transit and release of gastrointestinal peptides. Dig Dis Sci 1989; 34: 1511–1515
- Talley N J, Phillips S F, Miller L J, Haddad A. A specific 5HT3 antagonist delays colonic transit and inhibits postprandial neurotensin (NT) release. Gastroenterology 1988; 95: 891
- Talley N J, Phillips S F, Haddad A, et al. GR 38032F (ondansetron), a selective 5-HT3 receptor antagonist, slows colonic transit in healthy man. Dig Dis Sci 1990; 35: 477–480
- Gore S, Gilmore I T, Haigh C G, Bronwless S M, Stockdale H, Morris AI. Colonic transit in man is slowed by ondansetron (GR38032F) a selective 5-hydroxytryptamine receptor (type 3) antagonist. Aliment Pharmacol Ther 1990; 4: 139–144
- Nielson O H, Hvid-Jacobsen K, Lund P, Langholz E. Gastric emptying and subjective symptoms of nausea: Lack of effects of a 5-hydroxytryptamine-3 antagonist ondansetron on gastric emptying in patients with gastric stasis syndrome. Digestion 1990; 46: 89–96
- Steadman C J, Talley N J, Phillips S F, Mulvihill C. Trial of serotonin type 3 (5-HT3) receptor antagonist ondansetron (GR 38032F) in diarrhea predominant irritable bowel syndrome (IBS). Gastroenterology 1990; 98: A394
- Maxton D G, Haigh C G, Whorwell PJ. Clinical trial of ondansetron, a selective 5-HT3 antagonist in irritable bowel syndrome (IBS). Gastroenterology 1991; 100: A468
- Prior A, Read NW. Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5-HT3 receptor antagonist in patients with irritable bowel syndrome (IBS). Gut 1990; 31: A1174